Safety of cidofovir by intratympanic delivery technique

Jonette A. Ward, Douglas R. Sidell, Michel Nassar, Alisa L. Reece, Daniel I. Choo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Congenital cytomegalovirus (CMV) infection is one of the most common infectious causes of congenital sensorineural hearing loss. To date, a safe and effective therapy for CMV-induced hearing loss does not exist. We hypothesize that the antiviral cidofovir (CDV) can be delivered to the inner ear via intratympanic (IT) injections to safely and effectively mitigate CMV-induced hearing loss. Methods: To evaluate the safety of CDV IT injections, weanling guinea pigs with normal hearing were injected intratympanically with 3 mg or 5 mg concentrations of CDV and compared to control animals injected with sterile saline. A separate group of weanling guinea pigs were inoculated with CMV and a subset of this group was treated with CDV following inoculation. Results: The 3 mg/ml and 5 mg/ml CDV concentrations resulted in hearing loss following IT injection into uninfected animals. No signs of inflammation or toxicity were noted on histologic analysis and there was no evidence of systemic toxicity in serology. Hearing loss induced as a result of guinea pig CMV infection recovered by day 21 in animals treated with IT injections of 5 mg/ml CDV. Conclusions: We provide promising evidence demonstrating both the efficacy and safety of IT CDV in the guinea pig animal model. This research further establishes a sound framework upon which ongoing investigations into drug delivery mechanisms for CMV-induced hearing loss will be based.

Original languageEnglish (US)
Pages (from-to)97-105
Number of pages9
JournalAntiviral Therapy
Volume19
Issue number1
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Hearing Loss
Safety
Cytomegalovirus
Guinea Pigs
Cytomegalovirus Infections
Roseolovirus
Sensorineural Hearing Loss
Inner Ear
Serology
cidofovir
Hearing
Antiviral Agents
Animal Models
Inflammation
Intratympanic Injection
Research
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Ward, J. A., Sidell, D. R., Nassar, M., Reece, A. L., & Choo, D. I. (2014). Safety of cidofovir by intratympanic delivery technique. Antiviral Therapy, 19(1), 97-105. https://doi.org/10.3851/IMP2693

Safety of cidofovir by intratympanic delivery technique. / Ward, Jonette A.; Sidell, Douglas R.; Nassar, Michel; Reece, Alisa L.; Choo, Daniel I.

In: Antiviral Therapy, Vol. 19, No. 1, 2014, p. 97-105.

Research output: Contribution to journalArticle

Ward, JA, Sidell, DR, Nassar, M, Reece, AL & Choo, DI 2014, 'Safety of cidofovir by intratympanic delivery technique', Antiviral Therapy, vol. 19, no. 1, pp. 97-105. https://doi.org/10.3851/IMP2693
Ward, Jonette A. ; Sidell, Douglas R. ; Nassar, Michel ; Reece, Alisa L. ; Choo, Daniel I. / Safety of cidofovir by intratympanic delivery technique. In: Antiviral Therapy. 2014 ; Vol. 19, No. 1. pp. 97-105.
@article{aa235ddca0024feb845f2ff5dc58f742,
title = "Safety of cidofovir by intratympanic delivery technique",
abstract = "Background: Congenital cytomegalovirus (CMV) infection is one of the most common infectious causes of congenital sensorineural hearing loss. To date, a safe and effective therapy for CMV-induced hearing loss does not exist. We hypothesize that the antiviral cidofovir (CDV) can be delivered to the inner ear via intratympanic (IT) injections to safely and effectively mitigate CMV-induced hearing loss. Methods: To evaluate the safety of CDV IT injections, weanling guinea pigs with normal hearing were injected intratympanically with 3 mg or 5 mg concentrations of CDV and compared to control animals injected with sterile saline. A separate group of weanling guinea pigs were inoculated with CMV and a subset of this group was treated with CDV following inoculation. Results: The 3 mg/ml and 5 mg/ml CDV concentrations resulted in hearing loss following IT injection into uninfected animals. No signs of inflammation or toxicity were noted on histologic analysis and there was no evidence of systemic toxicity in serology. Hearing loss induced as a result of guinea pig CMV infection recovered by day 21 in animals treated with IT injections of 5 mg/ml CDV. Conclusions: We provide promising evidence demonstrating both the efficacy and safety of IT CDV in the guinea pig animal model. This research further establishes a sound framework upon which ongoing investigations into drug delivery mechanisms for CMV-induced hearing loss will be based.",
author = "Ward, {Jonette A.} and Sidell, {Douglas R.} and Michel Nassar and Reece, {Alisa L.} and Choo, {Daniel I.}",
year = "2014",
doi = "10.3851/IMP2693",
language = "English (US)",
volume = "19",
pages = "97--105",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "1",

}

TY - JOUR

T1 - Safety of cidofovir by intratympanic delivery technique

AU - Ward, Jonette A.

AU - Sidell, Douglas R.

AU - Nassar, Michel

AU - Reece, Alisa L.

AU - Choo, Daniel I.

PY - 2014

Y1 - 2014

N2 - Background: Congenital cytomegalovirus (CMV) infection is one of the most common infectious causes of congenital sensorineural hearing loss. To date, a safe and effective therapy for CMV-induced hearing loss does not exist. We hypothesize that the antiviral cidofovir (CDV) can be delivered to the inner ear via intratympanic (IT) injections to safely and effectively mitigate CMV-induced hearing loss. Methods: To evaluate the safety of CDV IT injections, weanling guinea pigs with normal hearing were injected intratympanically with 3 mg or 5 mg concentrations of CDV and compared to control animals injected with sterile saline. A separate group of weanling guinea pigs were inoculated with CMV and a subset of this group was treated with CDV following inoculation. Results: The 3 mg/ml and 5 mg/ml CDV concentrations resulted in hearing loss following IT injection into uninfected animals. No signs of inflammation or toxicity were noted on histologic analysis and there was no evidence of systemic toxicity in serology. Hearing loss induced as a result of guinea pig CMV infection recovered by day 21 in animals treated with IT injections of 5 mg/ml CDV. Conclusions: We provide promising evidence demonstrating both the efficacy and safety of IT CDV in the guinea pig animal model. This research further establishes a sound framework upon which ongoing investigations into drug delivery mechanisms for CMV-induced hearing loss will be based.

AB - Background: Congenital cytomegalovirus (CMV) infection is one of the most common infectious causes of congenital sensorineural hearing loss. To date, a safe and effective therapy for CMV-induced hearing loss does not exist. We hypothesize that the antiviral cidofovir (CDV) can be delivered to the inner ear via intratympanic (IT) injections to safely and effectively mitigate CMV-induced hearing loss. Methods: To evaluate the safety of CDV IT injections, weanling guinea pigs with normal hearing were injected intratympanically with 3 mg or 5 mg concentrations of CDV and compared to control animals injected with sterile saline. A separate group of weanling guinea pigs were inoculated with CMV and a subset of this group was treated with CDV following inoculation. Results: The 3 mg/ml and 5 mg/ml CDV concentrations resulted in hearing loss following IT injection into uninfected animals. No signs of inflammation or toxicity were noted on histologic analysis and there was no evidence of systemic toxicity in serology. Hearing loss induced as a result of guinea pig CMV infection recovered by day 21 in animals treated with IT injections of 5 mg/ml CDV. Conclusions: We provide promising evidence demonstrating both the efficacy and safety of IT CDV in the guinea pig animal model. This research further establishes a sound framework upon which ongoing investigations into drug delivery mechanisms for CMV-induced hearing loss will be based.

UR - http://www.scopus.com/inward/record.url?scp=84896902983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896902983&partnerID=8YFLogxK

U2 - 10.3851/IMP2693

DO - 10.3851/IMP2693

M3 - Article

C2 - 24153022

AN - SCOPUS:84896902983

VL - 19

SP - 97

EP - 105

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 1

ER -